The 36-month beta value for HUMA is also noteworthy at 1.96. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for HUMA is 125.45M, and at present, short sellers hold a 25.35% of that float. The average trading volume of HUMA on June 26, 2025 was 4.95M shares.
HUMA) stock’s latest price update
The stock price of Humacyte Inc (NASDAQ: HUMA) has dropped by -1.79 compared to previous close of 2.23. Despite this, the company has seen a fall of -6.01% in its stock price over the last five trading days. seekingalpha.com reported 2025-06-11 that Humacyte’s Symvess offers a significant clinical advance in vascular trauma, with strong efficacy and cost benefits over synthetic grafts and autologous vein grafts. The company targets a $200M-$480M annual revenue opportunity, depending on market penetration and future FDA approvals for expanded indications. Financial risks remain due to high cash burn and potential dilution, but current valuation appears reasonable given future growth prospects and insider buying.
HUMA’s Market Performance
HUMA’s stock has fallen by -6.01% in the past week, with a monthly drop of -13.44% and a quarterly drop of -23.83%. The volatility ratio for the week is 2.18% while the volatility levels for the last 30 days are 3.17% for Humacyte Inc The simple moving average for the last 20 days is -11.92% for HUMA’s stock, with a simple moving average of -41.38% for the last 200 days.
Analysts’ Opinion of HUMA
Many brokerage firms have already submitted their reports for HUMA stocks, with H.C. Wainwright repeating the rating for HUMA by listing it as a “Buy.” The predicted price for HUMA in the upcoming period, according to H.C. Wainwright is $4 based on the research report published on May 14, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see HUMA reach a price target of $15, previously predicting the price at $12. The rating they have provided for HUMA stocks is “Buy” according to the report published on December 20th, 2024.
H.C. Wainwright gave a rating of “Buy” to HUMA, setting the target price at $6 in the report published on December 11th of the previous year.
HUMA Trading at 9.62% from the 50-Day Moving Average
After a stumble in the market that brought HUMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.63% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HUMA starting from Scheessele William John, who purchase 6,493 shares at the price of $1.54 back on Apr 14 ’25. After this action, Scheessele William John now owns 22,018 shares of Humacyte Inc, valued at $9,999 using the latest closing price.
Sander Dale A., the CFO and Chief Corp. Deve. Off. of Humacyte Inc, purchase 20,000 shares at $1.53 during a trade that took place back on Apr 10 ’25, which means that Sander Dale A. is holding 40,600 shares at $30,600 based on the most recent closing price.
Stock Fundamentals for HUMA
Current profitability levels for the company are sitting at:
- -14.33 for the present operating margin
- 0.23 for the gross margin
The net margin for Humacyte Inc stands at -10.03. The total capital return value is set at -0.78. Equity return is now at value -257.38, with -49.40 for asset returns.
Based on Humacyte Inc (HUMA), the company’s capital structure generated 0.31 points at debt to capital in total, while cash flow to debt ratio is standing at -6.27. The debt to equity ratio resting at 0.44. The interest coverage ratio of the stock is -24.88.
Currently, EBITDA for the company is -132.23 million with net debt to EBITDA at 0.38. When we switch over and look at the enterprise to sales, we see a ratio of 37.79. The receivables turnover for the company is 15.87for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.68.
Conclusion
In summary, Humacyte Inc (HUMA) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
